Literature DB >> 16682430

Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins.

J Kim1, H A Reber, S M Dry, D Elashoff, S L Chen, N Umetani, M Kitago, O J Hines, K K Kazanjian, S Hiramatsu, A J Bilchik, S Yong, M Shoup, D S B Hoon.   

Abstract

BACKGROUND: Despite intent to cure surgery with negative resection margins, locoregional recurrence is common in pancreatic cancer. AIMS: To determine whether detection of K-ras gene mutation in the histologically negative surgical margins of pancreatic cancer reflects unrecognised disease. PATIENTS: Seventy patients who underwent curative resection for pancreatic ductal adenocarcinoma were evaluated.
METHODS: All patients had surgical resection margins (pancreatic transection and retroperitoneal) that were histologically free of invasive cancer. DNA was extracted from these paraffin embedded surgical margins and assessed by quantitative real time polymerase chain reaction to detect the K-ras gene mutation at codon 12. Detection of K-ras mutation was correlated with standard clinicopathological factors.
RESULTS: K-ras mutation was detected in histologically negative surgical margins of 37 of 70 (53%) patients. A significant difference in overall survival was demonstrated between patients with margins that were K-ras mutation positive compared with negative (median 15 v 55 months, respectively; p = 0.0008). By univariate and multivariate analyses, detection of K-ras mutation in the margins was a significant prognostic factor for poor survival (hazard ratio (HR) 2.8 (95% confidence interval (CI) 1.5-5.3), p = 0.0009; and HR 2.8 (95% CI 1.4-5.5), p = 0.004, respectively).
CONCLUSIONS: Detection of cells harbouring K-ras mutation in histologically negative surgical margins of pancreatic cancer may represent unrecognised disease and correlates with poor disease outcome. The study demonstrates that molecular-genetic evaluation of surgical resection margins can improve pathological staging and prognostic evaluation of patients with pancreatic ductal adenocarcinoma.

Entities:  

Mesh:

Year:  2006        PMID: 16682430      PMCID: PMC1860104          DOI: 10.1136/gut.2005.083063

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  42 in total

Review 1.  Genetic progression in the pancreatic ducts.

Authors:  R H Hruban; R E Wilentz; S E Kern
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

2.  Molecular margin analysis predicts local recurrence after sublobar resection of lung cancer.

Authors:  Brett G Masasyesva; Betty C Tong; Malcolm V Brock; Thomas Pilkington; David Goldenberg; David Sidransky; Susan Harden; William H Westra; Joseph Califano
Journal:  Int J Cancer       Date:  2005-03-01       Impact factor: 7.396

Review 3.  Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer.

Authors:  G D Sorenson
Journal:  Clin Cancer Res       Date:  2000-06       Impact factor: 12.531

4.  Activation of the c-K-ras oncogene in a human pancreas carcinoma.

Authors:  H Hirai; T Okabe; Y Anraku; M Fujisawa; A Urabe; F Takaku
Journal:  Biochem Biophys Res Commun       Date:  1985-02-28       Impact factor: 3.575

5.  KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas.

Authors:  V T Smit; A J Boot; A M Smits; G J Fleuren; C J Cornelisse; J L Bos
Journal:  Nucleic Acids Res       Date:  1988-08-25       Impact factor: 16.971

6.  Analysis of surgical margins with the molecular marker eIF4E: a prognostic factor in patients with head and neck cancer.

Authors:  C O Nathan; S Franklin; F W Abreo; R Nassar; A De Benedetti; J Glass
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

7.  Patterns of failure after curative resection of pancreatic carcinoma.

Authors:  J F Griffin; S R Smalley; W Jewell; J C Paradelo; R D Reymond; R E Hassanein; R G Evans
Journal:  Cancer       Date:  1990-07-01       Impact factor: 6.860

8.  Recurrence of exocrine pancreatic cancer--local or hepatic?

Authors:  J Westerdahl; A Andrén-Sandberg; I Ihse
Journal:  Hepatogastroenterology       Date:  1993-08

9.  Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy.

Authors:  C G Willett; K Lewandrowski; A L Warshaw; J Efird; C C Compton
Journal:  Ann Surg       Date:  1993-02       Impact factor: 12.969

10.  Clinical application of ras gene mutation for diagnosis of pancreatic adenocarcinoma.

Authors:  M Tada; M Omata; M Ohto
Journal:  Gastroenterology       Date:  1991-01       Impact factor: 22.682

View more
  29 in total

Review 1.  An unfavourable prognosis for pancreatic cancer indicates fields of opportunity.

Authors:  W Greenhalf
Journal:  Gut       Date:  2006-11       Impact factor: 23.059

Review 2.  Molecular markers of pancreatic cancer: development and clinical relevance.

Authors:  Lucia C Fry; Klaus Mönkemüller; Peter Malfertheiner
Journal:  Langenbecks Arch Surg       Date:  2008-02-12       Impact factor: 3.445

3.  Preoperative body composition is influenced by the stage of operable pancreatic adenocarcinoma but does not predict survival after Whipple's procedure.

Authors:  Alireza Aslani; Anthony J Gill; Paul J Roach; Barry J Allen; Ross C Smith
Journal:  HPB (Oxford)       Date:  2010-06       Impact factor: 3.647

4.  Screening for pancreatic cancer: current evidence and future directions.

Authors:  Julia B Greer; Randall E Brand
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-12

Review 5.  Surgical margins and its evaluation in oral cancer: a review.

Authors:  Spoorthi Banvar Ravi; Saileela Annavajjula
Journal:  J Clin Diagn Res       Date:  2014-09-20

6.  Molecular diagnosis of response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer.

Authors:  Zhenbin Chen; Marjun P Duldulao; Wenyan Li; Wendy Lee; Joseph Kim; Julio Garcia-Aguilar
Journal:  J Am Coll Surg       Date:  2011-03-31       Impact factor: 6.113

7.  Presence of pancreatic intraepithelial neoplasia in the pancreatic transection margin does not influence outcome in patients with R0 resected pancreatic cancer.

Authors:  Hanno Matthaei; Seung-Mo Hong; Skye C Mayo; Marco dal Molin; Kelly Olino; Raghunandan Venkat; Michael Goggins; Joseph M Herman; Barish H Edil; Christopher L Wolfgang; John L Cameron; Richard D Schulick; Anirban Maitra; Ralph H Hruban
Journal:  Ann Surg Oncol       Date:  2011-05-03       Impact factor: 5.344

Review 8.  Pancreatic cancer and the FAMMM syndrome.

Authors:  Henry T Lynch; Ramon M Fusaro; Jane F Lynch; Randall Brand
Journal:  Fam Cancer       Date:  2007-11-09       Impact factor: 2.375

9.  The value of diffusion-weighted imaging in assessing the ADC changes of tissues adjacent to breast carcinoma.

Authors:  Zhang Yili; Huang Xiaoyan; Du Hongwen; Zhang Yun; Chen Xin; Wang Peng; Guo Youmin
Journal:  BMC Cancer       Date:  2009-01-14       Impact factor: 4.430

10.  Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor.

Authors:  Stephen J Murphy; Steven N Hart; Joema Felipe Lima; Benjamin R Kipp; Mitchell Klebig; Jennifer L Winters; Csilla Szabo; Lizhi Zhang; Bruce W Eckloff; Gloria M Petersen; Steven E Scherer; Richard A Gibbs; Robert R McWilliams; George Vasmatzis; Fergus J Couch
Journal:  Gastroenterology       Date:  2013-08-02       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.